ICER Provides First Update to Pricing Models for Remdesivir as a Treatment for COVID-19

-- Updated cost-recovery benchmark price now framed as a range with maximum of $1,600 per 10-day regimen when incorporating assumptions regarding manufacturer’s 2020 development expenses, uptake of remdesivir, and consideration of early examples of real-world generic pricing --

-- Highlighted “cost-effectiveness” benchmark price shifts modestly higher to a range from $4,580 to $5,080 based on new peer-reviewed data on remdesivir; however, a new scenario analysis assuming the likely incorporation of dexamethasone as standard of care produces a lower benchmark price range for remdesivir of $2,520 to $2,800 --

-- Report contains additional scenario analyses to help policy makers debate what assumptions and pricing paradigms are most appropriate to achieve rapid development and distribution of treatments for a global pandemic --

Read More